版本:
中国

BRIEF-Redhill Biopharma provides progress update on RHB-104 Phase III crohn's disease program

Oct 6 Redhill Biopharma Ltd :

* Redhill Biopharma provides progress update on RHB104 Phase III crohn's disease program and introduces option for early stop for success in Q2/2017

* Independent safety-focused DSMB meeting for Phase III map US study is on track for Q4 of 2016

* Redhill will remain blinded to interim and ongoing results from Phase III study

* An independent safety-focused DSMB meeting for Phase III map US study is on track for Q4 of 2016

* No changes are planned to map US Phase III study's primary endpoint or 90% power Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐